Literature DB >> 23302415

Percutaneous nephrolithotomy for staghorn stones in patients with solitary kidney in prone position or in completely supine position: a single-center experience.

Yanbo Wang1, Yuchuan Hou, Fengming Jiang, Yan Wang, Chunxi Wang.   

Abstract

PURPOSE: To evaluate the effectivity and safety of percutaneous nephrolithotomy (PCNL) in the treatment of solitary kidney with staghorn stones in prone position or in completely supine position.
MATERIALS AND METHODS: We retrospectively reviewed the records of 18 patients with staghorn stones in a solitary kidney treated with PCNL. 12 patients underwent PCNL in prone position (group A). 6 patients underwent PCNL in completely supine position (group B). Demographic data, number of accesses, operating time, stone free rate, hemoglobin values, hospital stay and complications were studied. Serum creatinine, systolic and diastolic blood pressure, and new onset hypertension were determined preoperatively and postoperatively at 3 months.
RESULTS: No blood transfusions were required and no abdominal or thoracic organ injuries were reported in both groups. The mean operative time was 104 minutes (range: 72-145 minutes) and 128 minutes (range: 80-170 minutes), respectively. The I stage stone free rate was 91.7 % and 83.3 %, respectively. There was no new onset hypertension by the end of follow-up in both groups. Both groups showed a similar fall in serum creatinine at 3 month follow-up period (p = 0.004 and 0.029, respectively). Systolic blood pressure showed a statistically significant improvement in group B (p = 0.034).
CONCLUSION: PCNL is safe and has an acceptably high stone free rate in patients with solitary kidneys in both prone and completely supine position. At short-term follow-up, systolic blood pressure had improved in PCNL in supine position.

Entities:  

Mesh:

Year:  2012        PMID: 23302415     DOI: 10.1590/1677-553820133806788

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  7 in total

1.  Is the supine position superior to the prone position for percutaneous nephrolithotomy (PCNL)?

Authors:  Xiaohua Zhang; Leilei Xia; Tianyuan Xu; Xianjin Wang; Shan Zhong; Zhoujun Shen
Journal:  Urolithiasis       Date:  2013-10-20       Impact factor: 3.436

Review 2.  Prone Versus Supine Percutaneous Nephrolithotomy: What Is Your Position?

Authors:  Roshan M Patel; Zhamshid Okhunov; Ralph V Clayman; Jaime Landman
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

3.  Modified supine versus prone percutaneous nephrolithotomy: Surgical outcomes from a tertiary teaching hospital.

Authors:  Madeleine Nina Jones; Weranja Ranasinghe; Richard Cetti; Bradley Newell; Kevin Chu; Matthew Harper; John Kourambas; Philip McCahy
Journal:  Investig Clin Urol       Date:  2016-07-05

4.  Percutaneous nephrolithotomy in patients with solitary kidney: a critical outcome analysis.

Authors:  Fabio C M Torricelli; Guilherme P Padovani; Giovanni S Marchini; Fabio C Vicentini; Alexandre Danilovic; Sabrina T Reis; Miguel Srougi; Eduardo Mazzucchi
Journal:  Int Braz J Urol       Date:  2015 May-Jun       Impact factor: 1.541

Review 5.  Prone percutaneous nephrolithotomy: its advantages and our technique for puncture.

Authors:  Diego M Carrion; José Ramón Cansino; Luis M Quintana; Juan Gómez Rivas; Juan Antonio Mainez Rodriguez; José Ramón Pérez-Carral; Luis Martínez-Piñeiro
Journal:  Transl Androl Urol       Date:  2018-12

6.  Impact of patient position on the outcomes of percutaneous neprolithotomy for complex kidney stones.

Authors:  Fabio Carvalho Vicentini; Rodrigo Perrella; Vinicius M G Souza; Marcelo Hisano; Claudio Bovolenta Murta; Joaquim Francisco de Almeida Claro
Journal:  Int Braz J Urol       Date:  2018 Sep-Oct       Impact factor: 1.541

7.  Supine versus prone position in percutaneous nephrolithotomy: a systematic review and meta-analysis.

Authors:  Ponco Birowo; William Tendi; Indah S Widyahening; Nur Rasyid; Widi Atmoko
Journal:  F1000Res       Date:  2020-04-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.